Shoreline Biosciences, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sol-Gel Hopes To Bring PellePharm’s Pat

Gilead ’s cell therapy division Kite has signed a deal with a synthetic biology company Refuge Biotechnologies to help it to develop a next generation of CAR-T therapies. Kite is a leader in the f

As Stephen Rosen , head of the corporate practice in London at law firm Cooley observed, “We start 2022 in the rare position of the sector never having as high a profile amongst investors [as] it d

The momentum that biopharmaceutical companies gained in the eyes of investors in 2020 continued into 2021, delivering a record number of initial public offerings in the US for the second year in a row